ZETA Surgical Inc.

ZETA Surgical Inc. designs and manufactures AI-powered frameless neuronavigation systems for cranial surgery and neuromodulation procedures. The company's core platform, REALTRACK™, delivers real-time image-guided navigation with submillimeter accuracy and live continuous surgical guidance tracking patient movement at 20 times per second. The system eliminates the need for cranial pin fixation and general anesthesia, enabling bedside procedures in operating rooms, emergency settings, and ambulatory surgical centers. Primary clinical applications include external ventricular drain (ventriculostomy) placement, brain biopsy, transcranial magnetic stimulation (TMS) targeting, and tumor resection such as cavernoma removal. Clinical data demonstrates 100% single-pass catheter placement success for ventriculostomy (versus 81% freehand), 100% ideal placement (versus 32% freehand), zero adverse events and revision surgeries. The TMS Navigation System achieved FDA 510(k) clearance in October 2025. ZETA's technology integrates AI-based image analysis, ultra-fast system setup, and real-time guided intervention. The company is backed by leading neurosurgeons and research institutions including Harvard Medical School, Brigham and Women's Hospital, and Imperial College London. ZETA serves hospital operating rooms, neurosurgical centers, and interventional procedure suites primarily in the United States.